3,081 results on '"Armstrong, Paul W."'
Search Results
102. The relationship between meteorological conditions and index acute coronary events in a global clinical trial
103. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy
104. Medical Resource Use, Costs, and Quality of Life in Patients With Acute Decompensated Heart Failure: Findings From ASCEND-HF
105. Quantitative ST-depression in Acute Coronary Syndromes: the PLATO Electrocardiographic Substudy
106. Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non–ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends
107. Recalibrating Reperfusion Waypoints
108. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)
109. Insufficient reduction in heart rate during hospitalization despite beta‐blocker treatment in acute decompensated heart failure: insights from the ASCEND‐HF trial
110. Corrigendum to “Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial” [Am Heart J 169/6 (2015) 890–898]
111. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial
112. Diabetes and heart failure in the crosshairs: where is the target?
113. Relative Prognostic Value of Baseline Q Wave and Time from Symptom Onset Among Men and Women With ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
114. Serious Infection After Acute Myocardial Infarction: Incidence, Clinical Features, and Outcomes
115. Comparison of Incidence of Bleeding and Mortality of Men Versus Women With ST-Elevation Myocardial Infarction Treated With Fibrinolysis
116. Editorial July 2024.
117. Experimental Models of Heart Failure and Cardiomyopathy
118. Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk
119. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: A pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST
120. Determining the Cost Economic “Tipping Point” for the Addition of a Regional Percutaneous Coronary Intervention Facility
121. Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
122. Cardiogenic shock and heart failure post–percutaneous coronary intervention in ST-elevation myocardial infarction: Observations from “Assessment of Pexelizumab in Acute Myocardial Infarction”
123. Refining clinical trial composite outcomes: An application to the Assessment of the Safety and Efficacy of a New Thrombolytic–3 (ASSENT-3) trial
124. Temporal trends in patient and treatment delay among men and women presenting with ST-elevation myocardial infarction
125. Diagnosing Acute Myocardial Infarction in Patients With Left Bundle Branch Block
126. Are International Differences in the Outcomes of Acute Coronary Syndromes Apparent or Real? A Multilevel Analysis
127. Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial
128. Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF
129. Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction
130. Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes
131. Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy
132. The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF
133. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome
134. High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non–ST-segment elevation myocardial infarction
135. Medical Treatment of Unstable Angina and Acute Non-ST-Elevation Myocardial Infarction
136. Treatment of Acute ST-Elevation Myocardial Infarction
137. Coronary Heart Disease Syndromes: Pathophysiology and Clinical Recognition
138. Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
139. ST2 and mortality in non–ST-segment elevation acute coronary syndrome
140. Prior Coronary Artery Bypass Graft Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
141. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
142. Electrocardiographic identification of the culprit coronary artery in inferior wall ST elevation myocardial infarction
143. Usefulness of the QRS Score as a Strong Prognostic Marker in Patients Discharged After Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
144. Mechanical Complications After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction (from APEX-AMI)
145. Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial
146. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy
147. Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: Lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial
148. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: A substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial
149. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
150. Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.